Physician profile
Yoni Dokko
NPI 1518963636
$7,644.72
in general payments reported to CMS, 2019-2025
26 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $721 · 2021: $1,007 · 2022: $911 · 2023: $874 · 2024: $1,939 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,004.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,922.94 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Allergan, INC. | $648.14 | 2019-2022 | |
| Lundbeck LLC | $632.47 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $486.92 | 2019-2020 | |
| Pfizer INC. | $388.14 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $308.09 | 2019-2025 | Austedo Xr |
| Amgen INC. | $169.72 | 2019-2021 | |
| Tonix Medicines, INC. | $158.76 | 2024-2025 | Zembrace Symtouch |
| Ucb, INC. | $146.06 | 2019 | |
| Axsome Therapeutics, INC. | $140.25 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $99.11 | 2019-2020 | |
| Lilly USA, LLC | $96.21 | 2019-2024 | Emgality |
| Eisai INC. | $74.93 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.36 | 2022 | |
| Promius Pharma LLC | $44.78 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $34.72 | 2021 | |
| Sk Life Science, INC. | $33.84 | 2023 | |
| Impel Pharmaceuticals LLC | $33.34 | 2025 | Trudhesa |
| Medtronic, INC. | $32.20 | 2023 | Percept PC Brainsense |
| Neurocrine Biosciences, INC. | $25.38 | 2024 | Ingrezza |
| Genzyme Corporation | $24.42 | 2019 | |
| Scilex Pharmaceuticals INC. | $20.17 | 2023 | Ztlido |
| Biogen, INC. | $20.06 | 2021 | |
| Medtronic USA, INC. | $16.14 | 2020 | |
| Upsher-Smith Laboratories LLC | $15.91 | 2021 | |
| Acadia Pharmaceuticals INC | $15.66 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoni Dokko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.